Friday 5-16-2014 Allergan Inc (AGN) $AGN opened at
Post# of 58
Posted On: 05/17/2014 12:17:57 PM
Friday 5-16-2014 Allergan Inc (AGN) $AGN opened at 157.75 hitting the high price of 160.21 and a day low of 157.36 with a total volume of 2,688,600. AGN had a previous close of 158.89 and has been seeing an average volume of 6,364,835.
Overall Average: 24% Buy
Recent stock forum discussions about AGN http://investorshangout.com/search?q=AGN&...mp;yt0=Go!
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - 1 hr 26 mins ago
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S.... (full story)
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress. (full story)
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin). (full story)
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study. (full story)
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK. (full story)
Botox King Swings Back at "Unsustainable" Acquirer
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 16, 1:03PM CDT
Valeant Pharmaceuticals is on the hunt again, and its latest target is Botox king Allergan . Like many would-be acquisitions, Allergan isn't going down without a fight. Taking the position that Valeant's offer not only undervalues its business... (full story)
The Bellwether We've Searched For
at The Street - Fri May 16, 10:37AM CDT
You should be watching how DexCom is trading. (full story)
The Urology Care Foundation and Allergan Promote Patient Education and Advocacy at the 2014 American Urological Association Meeting
PR Newswire - Fri May 16, 7:30AM CDT
The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association (AUA), and Allergan, Inc. (NYSE: AGN) today announced the launch of two programs at the American Urological Association Annual Meeting May 16-21 in Orlando, FL, to support the Urology Care Foundation's effort in advancing urology research and patient education. (full story)
Acquisition Proposal Rejections, Court Rulings, Study Results, and Events Schedules - Analyst Notes on Allergan, Lilly, Amgen, Express Scripts and GSK
PR Newswire - Fri May 16, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Eli Lilly & Co. (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2533-100free. (full story)
Encouraging Data on Eli Lilly's Necitumumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 11:00AM CDT
Eli Lilly (LLY) announced encouraging results on its lung cancer candidate necitumumab from a phase III study. (full story)
Novartis Settles Gleevec Patent Litigation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:40AM CDT
Novartis (NVS) has settled its litigation with the subsidiary of Sun Pharmaceutical Industries Ltd. in the U.S. (full story)
Merck KGaA Beats on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:20AM CDT
Merck KGaA (MKGAF) reported 1Q14 earnings per ADR of $3.17, up 13.6% year over year and ahead of the Zacks Consensus Estimate of $2.35. (full story)
Research and Markets: Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
Business Wire - Thu May 15, 7:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tb4tpx/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering. (full story)
Rejected Proposals, Earnings Results, and Financial Outlook - Analyst Notes on Allergan, Isis, Depomed, Lannett and Orexigen
PR Newswire - Thu May 15, 6:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Depomed Inc. (NASDAQ: DEPO), Lannett Company, Inc. (NYSE: LCI) and Orexigen Therapeutics, Inc. (NYSE: OREX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2490-100free. (full story)
Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
M2 - Thu May 15, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc9ntj/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering. PHARMACEUTICALS MANUFACTURERS (Global) Analysis provides a detailed overview of the PHARMACEUTICALS MANUFACTURERS (Global) market and delivers a comprehensive individual analysis on the top 200 companies, including ALLERGAN INC, A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE - S.R.L. and BOIRON SA. This report includes a wealth of information on the financial trends over the past four years. Latest PHARMACEUTICALS MANUFACTURERS (Global) analysis is ideal for anyone wanting to: - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance A quick glance of this PHARMACEUTICALS MANUFACTURERS (Global) report will tell you that 25 companies have a declining Plimsoll financial rating, while 47 have shown good sales growth. Each of the largest 200 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings For more information visit http://www.researchandmarkets.com/research/cc...aceuticals (full story)
Merck Continues to Divest Ophthalmology Products - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 4:00PM CDT
Merck (MRK) entered into an agreement with Santen Pharmaceutical Co. to divest its ophthalmology products. (full story)
Allergan Up 27.0% Since SmarTrend Uptrend Call (AGN)
Comtex SmarTrend(R) - Wed May 14, 11:06AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 4 weeks, Allergan has returned 27.03% as of today's recent price of $160.01. (full story)
Pershing Square Eyes Nonbinding Vote on Allergan Bid
at The Street - Wed May 14, 9:41AM CDT
Bill Ackman's activist hedge fund Pershing Square Capital Management expects Allergan shareholders will have an opportunity as soon as next month to consider its proposal to have the Irvine, Calif.-based company engage in discussions over Canada's... (full story)
Healthcare Buyout Mania: Now What?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed May 14, 9:32AM CDT
It feels like there's nothing to talk about in the pharmaceutical space these days other than the latest M&A bid. Just in the last day and a half, investors have seen news on five completed or proposed transactions. And I doubt the deal-making is... (full story)
Dr. Reddy's Misses Q4 Earnings Ests, Beats on Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:30AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter 2014 earnings per ADS of 47 cents, missing the Zacks Consensus Estimate of 52 cents. (full story)
Overall Average: 24% Buy
Recent stock forum discussions about AGN http://investorshangout.com/search?q=AGN&...mp;yt0=Go!
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - 1 hr 26 mins ago
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S.... (full story)
Data on Novo Nordisk's NovoEight - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:30PM CDT
Novo Nordisk (NVO) recently announced positive interim data from its phase III trial, Guardian 2, on NovoEight at the World Federation of Haemophilia (WFH) World Congress. (full story)
Setback for Novartis' RLX030 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:10PM CDT
Novartis (NVS) suffered a setback when the FDA issued a CRL to its Biologics License Application (BLA) for pipeline candidate RLX030 (serelaxin). (full story)
Update on Glaxo's Darapladib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 4:00PM CDT
GlaxoSmithKline's (GSK) darapladib performed disappointingly in a phase III study. (full story)
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK. (full story)
Botox King Swings Back at "Unsustainable" Acquirer
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Fri May 16, 1:03PM CDT
Valeant Pharmaceuticals is on the hunt again, and its latest target is Botox king Allergan . Like many would-be acquisitions, Allergan isn't going down without a fight. Taking the position that Valeant's offer not only undervalues its business... (full story)
The Bellwether We've Searched For
at The Street - Fri May 16, 10:37AM CDT
You should be watching how DexCom is trading. (full story)
The Urology Care Foundation and Allergan Promote Patient Education and Advocacy at the 2014 American Urological Association Meeting
PR Newswire - Fri May 16, 7:30AM CDT
The Urology Care Foundation, the world's leading nonprofit urological health foundation and official foundation of the American Urological Association (AUA), and Allergan, Inc. (NYSE: AGN) today announced the launch of two programs at the American Urological Association Annual Meeting May 16-21 in Orlando, FL, to support the Urology Care Foundation's effort in advancing urology research and patient education. (full story)
Acquisition Proposal Rejections, Court Rulings, Study Results, and Events Schedules - Analyst Notes on Allergan, Lilly, Amgen, Express Scripts and GSK
PR Newswire - Fri May 16, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Eli Lilly & Co. (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Express Scripts Inc. (NASDAQ: ESRX) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2533-100free. (full story)
Encouraging Data on Eli Lilly's Necitumumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 11:00AM CDT
Eli Lilly (LLY) announced encouraging results on its lung cancer candidate necitumumab from a phase III study. (full story)
Novartis Settles Gleevec Patent Litigation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:40AM CDT
Novartis (NVS) has settled its litigation with the subsidiary of Sun Pharmaceutical Industries Ltd. in the U.S. (full story)
Merck KGaA Beats on Q1 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:20AM CDT
Merck KGaA (MKGAF) reported 1Q14 earnings per ADR of $3.17, up 13.6% year over year and ahead of the Zacks Consensus Estimate of $2.35. (full story)
Research and Markets: Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
Business Wire - Thu May 15, 7:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tb4tpx/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering. (full story)
Rejected Proposals, Earnings Results, and Financial Outlook - Analyst Notes on Allergan, Isis, Depomed, Lannett and Orexigen
PR Newswire - Thu May 15, 6:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Depomed Inc. (NASDAQ: DEPO), Lannett Company, Inc. (NYSE: LCI) and Orexigen Therapeutics, Inc. (NYSE: OREX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2490-100free. (full story)
Latest Pharmaceuticals Manufacturers Report - Individual Analysis On The Top 200 Companies, Including Allergan Inc, A. Menarini - Industrie Farmaceutiche Riunite - S.R.L. & Boiron Sa
M2 - Thu May 15, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cc9ntj/pharmaceuticals) has announced the addition of the "Pharmaceuticals Manufacturers (Global)" report to their offering. PHARMACEUTICALS MANUFACTURERS (Global) Analysis provides a detailed overview of the PHARMACEUTICALS MANUFACTURERS (Global) market and delivers a comprehensive individual analysis on the top 200 companies, including ALLERGAN INC, A. MENARINI - INDUSTRIE FARMACEUTICHE RIUNITE - S.R.L. and BOIRON SA. This report includes a wealth of information on the financial trends over the past four years. Latest PHARMACEUTICALS MANUFACTURERS (Global) analysis is ideal for anyone wanting to: - See the market leaders - Identify companies heading for failure - Seek out the most attractive acquisition - Analyse industry trends - Benchmark their own financial performance A quick glance of this PHARMACEUTICALS MANUFACTURERS (Global) report will tell you that 25 companies have a declining Plimsoll financial rating, while 47 have shown good sales growth. Each of the largest 200 companies is meticulously scrutinised in a one-page individual assessment and is analysed using the most up-to-date and current financial data. Every business is examined on the following features: - The Plimsoll Chart: A graphical assessment of a company's financial performance - Four year assessment of the profit/loss and balance sheet - A written summary highlighting key performance issues This section includes: - Best Trading Partners - Sales Growth Analysis - Profit Analysis - Market Size - Rankings For more information visit http://www.researchandmarkets.com/research/cc...aceuticals (full story)
Merck Continues to Divest Ophthalmology Products - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 4:00PM CDT
Merck (MRK) entered into an agreement with Santen Pharmaceutical Co. to divest its ophthalmology products. (full story)
Allergan Up 27.0% Since SmarTrend Uptrend Call (AGN)
Comtex SmarTrend(R) - Wed May 14, 11:06AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on April 15th, 2014 at $125.97. In approximately 4 weeks, Allergan has returned 27.03% as of today's recent price of $160.01. (full story)
Pershing Square Eyes Nonbinding Vote on Allergan Bid
at The Street - Wed May 14, 9:41AM CDT
Bill Ackman's activist hedge fund Pershing Square Capital Management expects Allergan shareholders will have an opportunity as soon as next month to consider its proposal to have the Irvine, Calif.-based company engage in discussions over Canada's... (full story)
Healthcare Buyout Mania: Now What?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed May 14, 9:32AM CDT
It feels like there's nothing to talk about in the pharmaceutical space these days other than the latest M&A bid. Just in the last day and a half, investors have seen news on five completed or proposed transactions. And I doubt the deal-making is... (full story)
Dr. Reddy's Misses Q4 Earnings Ests, Beats on Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 14, 9:30AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter 2014 earnings per ADS of 47 cents, missing the Zacks Consensus Estimate of 52 cents. (full story)
(0)
(0)Allergan Inc. (AGN) Stock Research Links
Scroll down for more posts ▼